Navigation Links
Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Date:11/19/2009

d by The Leukemia and Lymphoma Society of North America, and a Phase 1/2 randomized combination study with sorafenib in first-line hepatocellular carcinoma being conducted in Hong Kong.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing novel targeted therapies that address major unmet medical needs. In addition to AEG35156, Aegera is completing a Phase 2A study of AEG33773 in diabetic neuropathic pain and is working to progress HGS1029 through early stage clinical development with its partner Human Genome Sciences (HGSI). Additional information on these programs can be found on Aegera's website at www.aegera.com.

SOURCE AEGERA THERAPEUTICS INC.


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
2. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
3. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics welcomes two experienced executives to its board of directors
6. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
7. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
8. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
9. Fate Therapeutics Closes $30 Million Series B Financing
10. Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
11. Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... three large odour control systems for waste water treatment plants ... are consistent with the market resurgence in North ... CEO. "After a difficult period of restraint in our core ... sales growth. Our lower cost structure, technology improvements and supply ...
(Date:9/2/2014)... September 2, 2014 Culot brings ... and lab management services  BioData, producer of ... pleased to announce the appointment of Louis Culot ... served as VP Marketing and Business Development at BioDiscovery ... and clinical applications. Previously, Culot worked for ...
(Date:9/1/2014)... September 01, 2014 The global ... million by 2019 from $1,070.7 million in 2014, ... to 2019. The global oligonucleotide synthesis market is ... applications, end users, and geography. The synthesized oligonucleotides ... rate in the oligonucleotide synthesis market during the ...
(Date:8/31/2014)... (PRWEB) September 01, 2014 Available ... lighting needs for research and cultivation of a ... by Valoya’s proprietary LEDs with proven patented and ... ensures uncompromised light uniformity in critical applications in ... white LEDs. , “Our customers have a large ...
Breaking Biology Technology:Louis Culot Appointed as BioData's CEO 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... AMSTERDAM, November 11 Amsterdam Molecular,Therapeutics (Euronext: AMT), ... today that it has successfully treated Duchenne muscular dystrophy,(DMD) ... The proof of,concept studies were performed in collaboration with ... Sapienza, Italy) and demonstrated,effectiveness in the heart as well ...
... THE WOODLANDS, Texas, Nov. 10 Today, US ... , executive vice president and general counsel, will be ... http://www.newscom.com/cgi-bin/prnh/20091110/DA08765 ) , Watts has had a long ... worked with US Oncology providing legal services and consultation as ...
... , ST. LOUIS, Nov. 10 At the Board of ... dividend of $.145 per share, an 11.5% increase over the ... 2009 to shareholders of record on December 1, 2009. , ... Life Science and High Technology company. Our chemical and biochemical ...
Cached Biology Technology:AMT Successful in Preclinical Treatment of DMD 2AMT Successful in Preclinical Treatment of DMD 3US Oncology Announces Retirement of General Counsel Phil Watts 2
(Date:9/2/2014)... professional baseball pitchers with poor core stability are more likely ... because of injury than are pitchers who have good control ... the study, 347 pitchers were assessed for lumbopelvic control during ... they raised a leg to step up were up to ... cumulative, not consecutive during the season than were ...
(Date:9/2/2014)... issue of The FASEB Journal , ... the leading cause of blindness in adults, diabetic ... advance involves quantifying the early molecular changes caused ... Using new probes developed by scientists, they were ... diabetic retinopathy. , "My goal is to establish ...
(Date:9/2/2014)... September 2, 2014 Best-selling author Sam Kean stops ... the Megalodon, the 50-foot super shark that, despite what ... extinct. Learn all about it at http://youtu.be/KhFygIoW_MA . ... Tales of Madness, Love and the History of the ... getting the Reactions treatment in a 10-episode video series ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... pet rescue organizations are growing in number, working ... Although the majority of these organizations operate out ... winning high visibility for placing their pooches. , ... of the American Sociological Association (ASA) in Philadelphia, ...
... threatened by exotic species of the moon jellyfish being ... Using genetic data and computer simulations of ocean currents ... South Wales and the University of California, Davis, have ... naturally, according to a report in today's Proceedings of ...
... new study has found that the allergenicity of peanut ... process. Researchers from North Carolina A&T University report their ... American Society for Microbiology. , "Due to the wide ... snacks and even soups there is a need to ...
Cached Biology News:Virtual animal shelters ?How the Internet is transforming the experience of pet adoptions 2Ships bring alien jellyfish invaders to our shores 2
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
...
Request Info...
Biology Products: